- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
Market Overview
The CAR-T Therapy in Haematological Malignancy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The most likely (base case) scenario is that the global CAR-T Therapy in Haematological Malignancy sales will be xx in 2020 from CAR-T Therapy in Haematological Malignancy million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global CAR-T Therapy in Haematological Malignancy market size is expected to grow at xx% or more annually for the next five years.
This report also researches and evaluates the impact of Covid-19 outbreak on the CAR-T Therapy in Haematological Malignancy industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on CAR-T Therapy in Haematological Malignancy and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Market segmentation
CAR-T Therapy in Haematological Malignancy market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for revenue by Type and Application. This analysis can help you expand your business by targeting qualified niche markets.
Breakdown by Type, CAR-T Therapy in Haematological Malignancy market has been segmented into Allogeneic, Autologous, etc.
Breakdown by Application, CAR-T Therapy in Haematological Malignancy has been segmented into Hospitals, Cancer Research Centers, Others, etc.
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global CAR-T Therapy in Haematological Malignancy market presented in the report. This section sheds light on the sales growth of different regional and country-level CAR-T Therapy in Haematological Malignancy markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global CAR-T Therapy in Haematological Malignancy market.
For Japan, this report analyses the Japan market by players, Type and Application, for the period 2015-2025.
Competitive Landscape and CAR-T Therapy in Haematological Malignancy Market Share Analysis
CAR-T Therapy in Haematological Malignancy competitive landscape provides details by vendors, including company overview, company total revenue, market potential, global presence, CAR-T Therapy in Haematological Malignancy revenue generated, market share, headquarters, SWOT analysis, product launch. For the period 2015-2020, this study provides the CAR-T Therapy in Haematological Malignancy revenue and market share for each player covered in this report.
The major players covered in CAR-T Therapy in Haematological Malignancy are: Celgene (Juno Therapeutics), Sorrento Therapeutics, Pfizer, Novartis, Aurora BioPharma, Gilead (Kite Pharma), Bluebird Bio, Autolus Therapeutics, CARsgen Therapeutics, Mustang Bio, Collectis, Allogene Therapeutics, Celyad, etc. Among other players domestic and global, CAR-T Therapy in Haematological Malignancy market share data is available for global, North America, Europe, Asia, Middle East and Africa and South America separately. Our analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Market segment by players, this report covers
Celgene (Juno Therapeutics)
Sorrento Therapeutics
Pfizer
Novartis
Aurora BioPharma
Gilead (Kite Pharma)
Bluebird Bio
Autolus Therapeutics
CARsgen Therapeutics
Mustang Bio
Collectis
Allogene Therapeutics
Celyad
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina)
MENA (Saudi Arabia, UAE, Turkey and South Africa)
Market segment by Type, covers:
Allogeneic
Autologous
Market segment by Application, can be divided into
Hospitals
Cancer Research Centers
Others
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of CAR-T Therapy in Haematological Malignancy
1.2 Classification of CAR-T Therapy in Haematological Malignancy by Type
1.2.1 Overview: Global CAR-T Therapy in Haematological Malignancy Revenue by Type: 2015 Versus 2019 Versus 2025
1.2.2 Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type in 2019
1.2.3 Allogeneic
1.2.4 Autologous
1.3 Global CAR-T Therapy in Haematological Malignancy Market by Application
1.3.1 Overview: Global CAR-T Therapy in Haematological Malignancy Revenue by Application: 2015 Versus 2019 Versus 2025
1.3.2 Hospitals
1.3.3 Cancer Research Centers
1.3.4 Others
1.4 Global CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
1.5 Global CAR-T Therapy in Haematological Malignancy Market Size by Regions: 2015 VS 2019 VS 2025
1.6 Global CAR-T Therapy in Haematological Malignancy Market Size by Regions (2015-2020)
1.7 Global CAR-T Therapy in Haematological Malignancy Market Size and Forecast by Regions (2020-2025)
1.7.1 North America CAR-T Therapy in Haematological Malignancy Status and Prospect (2015-2025)
1.7.2 Europe CAR-T Therapy in Haematological Malignancy Status and Prospect (2015-2025)
1.7.3 Asia CAR-T Therapy in Haematological Malignancy Status and Prospect (2015-2025)
1.7.4 South America CAR-T Therapy in Haematological Malignancy Status and Prospect (2015-2025)
1.7.5 Middle East & Africa CAR-T Therapy in Haematological Malignancy Status and Prospect (2015-2025)
1.8 COVID-19 Outbreak: CAR-T Therapy in Haematological Malignancy Industry Impact
1.8.1 COVID-19 Potential Implications for the CAR-T Therapy in Haematological Malignancy
1.8.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on CAR-T Therapy in Haematological Malignancy
1.8.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.8.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.8.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.8.2 Opportunity Analysis in Covid-19 Crisis
1.8.3 Market Risk and Restraints
1.8.4 Market Driving Force
2 Company Profiles
2.1 Celgene (Juno Therapeutics)
2.1.1 Celgene (Juno Therapeutics) Details
2.1.2 Celgene (Juno Therapeutics) Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Celgene (Juno Therapeutics) SWOT Analysis
2.1.4 Celgene (Juno Therapeutics) Product and Services
2.1.5 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.2 Sorrento Therapeutics
2.2.1 Sorrento Therapeutics Details
2.2.2 Sorrento Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Sorrento Therapeutics SWOT Analysis
2.2.4 Sorrento Therapeutics Product and Services
2.2.5 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Pfizer SWOT Analysis
2.3.4 Pfizer Product and Services
2.3.5 Pfizer CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Novartis SWOT Analysis
2.4.4 Novartis Product and Services
2.4.5 Novartis CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.5 Aurora BioPharma
2.5.1 Aurora BioPharma Details
2.5.2 Aurora BioPharma Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Aurora BioPharma SWOT Analysis
2.5.4 Aurora BioPharma Product and Services
2.5.5 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.6 Gilead (Kite Pharma)
2.6.1 Gilead (Kite Pharma) Details
2.6.2 Gilead (Kite Pharma) Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Gilead (Kite Pharma) Product and Services
2.6.4 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.7 Bluebird Bio
2.7.1 Bluebird Bio Details
2.7.2 Bluebird Bio Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Bluebird Bio Product and Services
2.7.4 Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.8 Autolus Therapeutics
2.8.1 Autolus Therapeutics Details
2.8.2 Autolus Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Autolus Therapeutics Product and Services
2.8.4 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.9 CARsgen Therapeutics
2.9.1 CARsgen Therapeutics Details
2.9.2 CARsgen Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 CARsgen Therapeutics Product and Services
2.9.4 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.10 Mustang Bio
2.10.1 Mustang Bio Details
2.10.2 Mustang Bio Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Mustang Bio Product and Services
2.10.4 Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.11 Collectis
2.11.1 Collectis Details
2.11.2 Collectis Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Collectis Product and Services
2.11.4 Collectis CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.12 Allogene Therapeutics
2.12.1 Allogene Therapeutics Details
2.12.2 Allogene Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Allogene Therapeutics Product and Services
2.12.4 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.13 Celyad
2.13.1 Celyad Details
2.13.2 Celyad Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Celyad Product and Services
2.13.4 Celyad CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global CAR-T Therapy in Haematological Malignancy Market Size by Players (2015-2020)
3.2 Japan CAR-T Therapy in Haematological Malignancy Market Size by Players (2015-2020)
3.3 Market Concentration Rate
3.3.1 Top 5 CAR-T Therapy in Haematological Malignancy Players Market Share
3.3.2 Top 10 CAR-T Therapy in Haematological Malignancy Players Market Share
4 North America Market Size and Forecast by Countries
4.1 North America CAR-T Therapy in Haematological Malignancy Market Size by Countries (2015-2020)
4.2 North America CAR-T Therapy in Haematological Malignancy Market Size and Forecast by Countries (2015-2026)
4.3 United States CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
4.4 Canada CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
4.5 Mexico CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
5 Europe Market Size and Forecast by Countries
5.1 Europe CAR-T Therapy in Haematological Malignancy Market Size by Countries (2015-2020)
5.2 Europe CAR-T Therapy in Haematological Malignancy Market Size and Forecast by Countries (2015-2026)
5.3 Germany CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
5.4 France CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
5.5 UK CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
5.6 Russia CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
5.7 Italy CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
6 Asia-Pacific Market Size and Forecast by Countries
6.1 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Regions (2015-2020)
6.2 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size and Forecast by Regions (2015-2026)
6.3 China CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
6.4 Japan CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
6.5 Korea CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
6.6 India CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
6.7 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
7 South America Market Size and Forecast by Countries
7.1 South America CAR-T Therapy in Haematological Malignancy Market Size by Countries (2015-2020)
7.2 South America CAR-T Therapy in Haematological Malignancy Market Size and Forecast by Countries (2015-2026)
7.3 Brazil CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
7.4 Argentina CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
8 Middle East & Africa Market Size and Forecast by Countries
8.1 Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue by Regions (2015-2020)
8.2 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size and Forecast by Countries (2015-2026)
8.3 Saudi Arabia CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
8.4 UAE CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
8.5 Egypt CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
8.6 South Africa CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
9 Market Size Segment by Type
9.1 Global CAR-T Therapy in Haematological Malignancy Market Size and Forecast by Type (2015-2025)
9.1.1 Global CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)
9.1.2 Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Type (2020-2025)
9.2 Japan CAR-T Therapy in Haematological Malignancy Market Size and Forecast by Type (2015-2025)
9.2.1 Japan CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)
9.2.2 Japan CAR-T Therapy in Haematological Malignancy Market Size Forecast by Type (2020-2025)
10 Market Size Segment by Application
10.1 Global CAR-T Therapy in Haematological Malignancy Market Size and Forecast by Application (2015-2025)
10.1.1 Global CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)
10.1.2 Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Application (2020-2025)
10.2 Japan CAR-T Therapy in Haematological Malignancy Market Size and Forecast by Application (2015-2025)
10.2.1 Japan CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)
10.2.2 Japan CAR-T Therapy in Haematological Malignancy Market Size Forecast by Application (2020-2025)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Data Source
12.3 Disclaimer
12.4 About US
List of Tables
Table 1. Global CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Type: 2015 Versus 2019 Versus 2025
Table 2. Breakdown of CAR-T Therapy in Haematological Malignancy by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Application: 2015 Versus 2019 Versus 2025
Table 4. Global Market CAR-T Therapy in Haematological Malignancy Market Size (USD Million) Comparison by Regions (2020-2025)
Table 5. Global CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Regions (2015-2020)
Table 6. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Regions (2015-2020)
Table 7. Global CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Regions (2020-2025)
Table 8. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Regions (2020-2025)
Table 9. Global CAR-T Therapy in Haematological Malignancy Market Size and Growth Estimation in Various Scenarios in 2020
Table 10. Celgene (Juno Therapeutics) Corporate Information, Location and Competitors
Table 11. Celgene (Juno Therapeutics) Major Business
Table 12. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 13. Celgene (Juno Therapeutics) SWOT Analysis
Table 14. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 15. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 16. Sorrento Therapeutics Corporate Information, Location and Competitors
Table 17. Sorrento Therapeutics Major Business
Table 18. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2018-2019)
Table 19. Sorrento Therapeutics SWOT Analysis
Table 20. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 21. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 22. Pfizer Corporate Information, Location and Competitors
Table 23. Pfizer Major Business
Table 24. Pfizer CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 25. Pfizer SWOT Analysis
Table 26. Pfizer CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 27. Pfizer CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 28. Novartis Corporate Information, Location and Competitors
Table 29. Novartis Major Business
Table 30. Novartis CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 31. Novartis SWOT Analysis
Table 32. Novartis CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 33. Novartis CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 34. Aurora BioPharma Corporate Information, Location and Competitors
Table 35. Aurora BioPharma Major Business
Table 36. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 37. Aurora BioPharma SWOT Analysis
Table 38. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 39. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 40. Gilead (Kite Pharma) Corporate Information, Location and Competitors
Table 41. Gilead (Kite Pharma) Major Business
Table 42. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 43. Gilead (Kite Pharma) SWOT Analysis
Table 44. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 45. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 46. Bluebird Bio Corporate Information, Location and Competitors
Table 47. Bluebird Bio Major Business
Table 48. Bluebird Bio CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 49. Bluebird Bio SWOT Analysis
Table 50. Bluebird Bio CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 51. Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 52. Autolus Therapeutics Corporate Information, Location and Competitors
Table 53. Autolus Therapeutics Major Business
Table 54. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 55. Autolus Therapeutics SWOT Analysis
Table 56. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 57. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 58. CARsgen Therapeutics Corporate Information, Location and Competitors
Table 59. CARsgen Therapeutics Major Business
Table 60. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 61. CARsgen Therapeutics SWOT Analysis
Table 62. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 63. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 64. Mustang Bio Corporate Information, Location and Competitors
Table 65. Mustang Bio Major Business
Table 66. Mustang Bio CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 67. Mustang Bio SWOT Analysis
Table 68. Mustang Bio CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 69. Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 70. Collectis Corporate Information, Location and Competitors
Table 71. Collectis Major Business
Table 72. Collectis CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 73. Collectis SWOT Analysis
Table 74. Collectis CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 75. Collectis CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 76. Allogene Therapeutics Corporate Information, Location and Competitors
Table 77. Allogene Therapeutics Major Business
Table 78. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 79. Allogene Therapeutics SWOT Analysis
Table 80. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 81. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 82. Celyad Corporate Information, Location and Competitors
Table 83. Celyad Major Business
Table 84. Celyad CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 85. Celyad SWOT Analysis
Table 86. Celyad CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 87. Celyad CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 88. Global CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Players (2015-2020)
Table 89. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Players (2015-2020)
Table 90. Key Players CAR-T Therapy in Haematological Malignancy Revenue (USD Million) in Japan (2015-2020)
Table 91. Key Players CAR-T Therapy in Haematological Malignancy Revenue Share in Japan (2015-2020)
Table 92. North America CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Countries (2015-2020)
Table 93. North America CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries (2015-2020)
Table 94. North America CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Countries (2020-2026)
Table 95. North America CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries (2020-2026)
Table 96. Europe CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Countries (2015-2020)
Table 97. Europe CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries (2015-2020)
Table 98. Europe CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Countries (2020-2026)
Table 99. Europe CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries (2020-2026)
Table 100. Asia-Pacific CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Countries (2015-2020)
Table 101. Asia-Pacific CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries (2015-2020)
Table 102. Asia-Pacific CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Countries (2020-2026)
Table 103. Asia-Pacific CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries (2020-2026)
Table 104. South America CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Countries (2015-2020)
Table 105. South America CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries (2015-2020)
Table 106. South America CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Countries (2020-2026)
Table 107. South America CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries (2020-2026)
Table 108. Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Countries (2015-2020)
Table 109. Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries (2015-2020)
Table 110. Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Countries (2020-2026)
Table 111. Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries (2020-2026)
Table 112. Global CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Type (2015-2020)
Table 113. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Type (2015-2020)
Table 114. Global CAR-T Therapy in Haematological Malignancy Revenue Forecast by Type (2020-2025)
Table 115. Global CAR-T Therapy in Haematological Malignancy Market Share Forecast by Type (2020-2025)
Table 116. Japan CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Type (2015-2020)
Table 117. Japan CAR-T Therapy in Haematological Malignancy Revenue Share by Type (2015-2020)
Table 118. Japan CAR-T Therapy in Haematological Malignancy Revenue Forecast by Type (2020-2025)
Table 119. Japan CAR-T Therapy in Haematological Malignancy Market Share Forecast by Type (2020-2025)
Table 120. Global CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Application (2015-2020)
Table 121. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Application (2015-2020)
Table 122. Global CAR-T Therapy in Haematological Malignancy Revenue Forecast by Application (2020-2025)
Table 123. Global CAR-T Therapy in Haematological Malignancy Market Share Forecast by Application (2020-2025)
Table 124. Japan CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Application (2015-2020)
Table 125. Japan CAR-T Therapy in Haematological Malignancy Revenue Share by Application (2015-2020)
Table 126. Japan CAR-T Therapy in Haematological Malignancy Revenue Forecast by Application (2020-2025)
Table 127. Japan CAR-T Therapy in Haematological Malignancy Market Share Forecast by Application (2020-2025)
Table 128.List of Figures
Table 129. CAR-T Therapy in Haematological Malignancy Picture
Table 130. Global CAR-T Therapy in Haematological Malignancy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Table 131. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type in 2019
Table 132. Allogeneic Picture
Table 133. Autologous Picture
Table 134. CAR-T Therapy in Haematological Malignancy Revenue Market Share by Application in 2019
Table 135. Hospitals Picture
Table 136. Cancer Research Centers Picture
Table 137. Others Picture
Table 138. Global CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2025) (USD Million)
Table 139. Global CAR-T Therapy in Haematological Malignancy Market Size Share by Regions (2015-2025)
Table 140. Global CAR-T Therapy in Haematological Malignancy Market Size Share by Regions in 2019
Table 141. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Regions (2020-2025)
Table 142. North America CAR-T Therapy in Haematological Malignancy Revenue (USD Million) and Growth Rate (2015-2025)
Table 143. Europe CAR-T Therapy in Haematological Malignancy Revenue (USD Million) and Growth Rate (2015-2025)
Table 144. Asia-Pacific CAR-T Therapy in Haematological Malignancy Revenue (USD Million) and Growth Rate (2015-2025)
Table 145. South America CAR-T Therapy in Haematological Malignancy Revenue (USD Million) and Growth Rate (2015-2025)
Table 146. Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue (USD Million) and Growth Rate (2015-2025)
Table 147. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Players in 2019
Table 148. Global Top 5 Players CAR-T Therapy in Haematological Malignancy Revenue Market Share in 2019
Table 149. Top 10 Players CAR-T Therapy in Haematological Malignancy Revenue Market Share in Global Market in 2019
Table 150. Global CAR-T Therapy in Haematological Malignancy Market Size (USD Million) by Type (2015-2025)
Table 151. Global CAR-T Therapy in Haematological Malignancy Market Size Share by Application (2015-2025)
Table 152. North America CAR-T Therapy in Haematological Malignancy Market Size Share by Countries (2015-2025)
Table 153. North America CAR-T Therapy in Haematological Malignancy Market Size Share by Countries in 2019
Table 154. United States CAR-T Therapy in Haematological Malignancy Market Size (USD Million) and Forecast (2015-2025)
Table 155. Canada CAR-T Therapy in Haematological Malignancy Market Size (USD Million) and Forecast (2015-2025)
Table 156. Mexico CAR-T Therapy in Haematological Malignancy Market Size (USD Million) and Forecast (2015-2025)
Table 157. Europe CAR-T Therapy in Haematological Malignancy Market Size Share by Countries (2015-2025)
Table 158. Europe CAR-T Therapy in Haematological Malignancy Market Size Share by Countries in 2019
Table 159. Germany CAR-T Therapy in Haematological Malignancy Market Size (USD Million) and Forecast (2015-2025)
Table 160. France CAR-T Therapy in Haematological Malignancy Market Size (USD Million) and Forecast (2015-2025)
Table 161. Russia CAR-T Therapy in Haematological Malignancy Market Size (USD Million) and Forecast (2015-2025)
Table 162. Italy CAR-T Therapy in Haematological Malignancy Market Size (USD Million) and Forecast (2015-2025)
Table 163. Spain CAR-T Therapy in Haematological Malignancy Market Size (USD Million) and Forecast (2015-2025)
Table 164. UK CAR-T Therapy in Haematological Malignancy Market Size (USD Million) and Forecast (2015-2025)
Table 165. Asia CAR-T Therapy in Haematological Malignancy Market Size Share by Countries (2015-2025)
Table 166. Asia CAR-T Therapy in Haematological Malignancy Market Size Share by Countries in 2019
Table 167. China CAR-T Therapy in Haematological Malignancy Market Size (USD Million) and Forecast (2015-2025)
Table 168. Japan CAR-T Therapy in Haematological Malignancy Market Size (USD Million) and Forecast (2015-2025)
Table 169. Korea CAR-T Therapy in Haematological Malignancy Market Size (USD Million) and Forecast (2015-2025)
Table 170. India CAR-T Therapy in Haematological Malignancy Market Size (USD Million) and Forecast (2015-2025)
Table 171. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size (USD Million) and Forecast (2015-2025)
Table 172. South America CAR-T Therapy in Haematological Malignancy Market Size Share by Countries (2015-2025)
Table 173. South America CAR-T Therapy in Haematological Malignancy Market Size Share by Countries in 2019
Table 174. Brazil CAR-T Therapy in Haematological Malignancy Market Size (USD Million) and Forecast (2015-2025)
Table 175. Argentina CAR-T Therapy in Haematological Malignancy Market Size (USD Million) and Forecast (2015-2025)
Table 176. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Share by Countries (2015-2025)
Table 177. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Share by Countries in 2019
Table 178. Saudi Arabia CAR-T Therapy in Haematological Malignancy Market Size (USD Million) and Forecast (2015-2025)
Table 179. UAE CAR-T Therapy in Haematological Malignancy Market Size (USD Million) and Forecast (2015-2025)
Table 180. Egypt CAR-T Therapy in Haematological Malignancy Market Size (USD Million) and Forecast (2015-2025)
Table 181. South Africa CAR-T Therapy in Haematological Malignancy Market Size (USD Million) and Forecast (2015-2025)
Table 182. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Type (2015-2020)
Table 183. Japan CAR-T Therapy in Haematological Malignancy Revenue Share by Type (2015-2020)
Table 184. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Application (2015-2020)
Table 185. Japan CAR-T Therapy in Haematological Malignancy Revenue Share by Application (2015-2020)
Please feel free to write an email to us or to use our electronic ticketing system.
